I'm LongbridgeAI, I can summarize articles.In Thursday's pre-market session, healthcare stocks showed significant volatility. Gainers included Virax Biolabs (VRAX) up 134%, Alnylam Pharmaceuticals (ALNY) up 17.7%, and Bluejay Diagnostics (BJDX) up 14.92%. Conversely, losers featured Ionis Pharmaceuticals (IONS) down 21.9%, Catheter Precision (VTAK) down 18.89%, and Aptevo Therapeutics (APVO) down 14.45%.
Gainers
- Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million.
- Alnylam Pharmaceuticals (NASDAQ:ALNY) stock moved upwards by 17.7% to $380.76. The market value of their outstanding shares is at $43.1 billion.
- Bluejay Diagnostics (NASDAQ:BJDX) shares rose 14.92% to $1.54. The company's market cap stands at $1.3 million.
- BridgeBio Pharma (NASDAQ:BBIO) shares rose 12.66% to $88.25. The market value of their outstanding shares is at $15.3 billion.
- VivoSim Labs (NASDAQ:VIVS) stock increased by 11.16% to $0.87. The company's market cap stands at $2.2 million.
- Oncolytics Biotech (NASDAQ:ONCY) stock increased by 9.8% to $0.87. The company's market cap stands at $94.5 million.
Losers
- Ionis Pharmaceuticals (NASDAQ:IONS) shares decreased by 21.9% to $66.0 during Thursday's pre-market session. The company's market cap stands at $13.9 billion.
- Catheter Precision (AMEX:VTAK) shares declined by 18.89% to $1.11. The company's market cap stands at $4.9 million.
- Aptevo Therapeutics (NASDAQ:APVO) shares decreased by 14.45% to $3.85. The company's market cap stands at $5.6 million.
- Tvardi Therapeutics (NASDAQ:TVRD) shares decreased by 9.4% to $4.53. The market value of their outstanding shares is at $46.9 million.
- AEON Biopharma (AMEX:AEON) shares declined by 8.5% to $0.64. The market value of their outstanding shares is at $18.4 million.
- Shuttle Pharmaceuticals (NASDAQ:SHPH) stock declined by 8.41% to $3.27. The company's market cap stands at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.